OBJECTIVE To evaluate the predictive value of humanepidermal growth factor receptor-2 (HER-2) and P53 in taxane-based and anthracycline-based neoadjuvant chemotherapy (NAC)in breast cancer.METHODSSixty-two patients with breast cancer wereincluded in this study.Twenty-two patients were treated withtaxane-based (taxane group) and 40 with anthracycline-based(anthracycline group).ER,PR,c-erbB2 and P53 were detected byimmunohistochemistry staining before NAC,and FluorescenceIn Situ Hybridization(FISH) was used to detect the HER-2 geneamplification for the cases with the expression of c-erbB2 proteinas (++) or (+++).The efficacy of the regimens was evaluated afterNAC.RESULTS In the anthracycline group,objective response (OR)was observed in 30 out of 40 patients (75%),whereas no response(NR) was observed in 10 patients (25%).In the taxane group,ORwas observed in 15 patients out of 22 patients (68.2%),whereasNR was observed in 7 patients (31.8%).HER-2-negative status wascorrelated with a high OR in both taxane-based and anthracycline-based NAC (P = 0.023 and P = 0.029),whereas P53-negative statuswas correlated with high OR rate in anthracycline-based NAC (P= 0.041).The significant difference of the CR rates was observedbetween the patients took<4 cycles and>4 cycles NAC (4.65% vs.21.05%,P<0.05).CONCLUSION The patients with HER-2 gene non-amplicationmay be sensitive to both taxane-based and anthracycline-basedchemotherapy;the patients without P53 overexpression maysuitable to select anthracycline-based chemotherapy;and properincreased NAC cycles may increase CR rates. OBJECTIVE To evaluate the predictive value of humanepidermal growth factor receptor-2 (HER-2) and P53 in taxane-based and anthracycline-based neoadjuvant chemotherapy (NAC) in breast cancer. METHODSSixty-two patients with breast cancer wereincluded in this study.Twenty -two patients were treated withtaxane-based (taxane group) and 40 with anthracycline-based (anthracycline group) .ER, PR, c-erbB2 and P53 were detected byimmunohistochemistry staining before NAC, and FluorescenceIn Situ Hybridization (FISH) was used to detect the HER-2 gene amplification for the cases with the expression of c-erbB2 proteinas (++) or (+++). The efficacy of the regimens was evaluated after NAC.RESULTS In the anthracycline group, objective response (OR) was observed in In the taxane group, OR was observed in 15 patients out of 22 patients (68.2%), while NRR was observed in 7 (25%). patients (31.8%). HER-2-negative status wascorrelated with a high OR in both taxane-based and anthracycline-based NAC (P = 0.023 and P = 0.029), P53-negative statuswas correlated with high OR rate in anthracycline-based NAC (P = 0.041). The significant difference of the CR rates was observedbetween the patients took <4 cycles and> 4 cycles NAC (4.65% vs.21.05%, P <0.05) .CONCLUSION The patients with HER-2 gene non-amplicationmay be sensitive to both taxane-based and anthracycline-based chemotherapy; the patients without P53 overexpression maysuitable to select anthracycline-based chemotherapy; and proper increased NAC cycles may increase CR rates.